Adrenomed AG is a German privately-financed, clinical stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the Company’s lead product candidate is Adrecizumab, a clinical-stage, first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab is currently under clinical evaluation in a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II study with 300 patients suffering septic shock. Excellent safety and tolerability were demonstrated in two Phase I trials.
Affibody is a private clinical-stage Swedish biotech company focused on developing into an integrated biopharma company utilizing next generation biotherapeutics based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
The company operates a focused experimental medicine model and currently has three clinical stage programs. The first two are therapeutic programs that target psoriasis and rare Immunoglobulin G (IgG)-mediated autoimmune diseases. The third program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer.
In addition, to its portfolio of innovative drug projects the company offers the half-life extension technology, Albumod™, for outlicensing.
Affimed is a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK® platform allows innate cell engagers to be designed for specific patient populations. The Company is developing single and combination therapies to treat cancers.
Amryt is a commercial stage pharmaceutical company, focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to address some of these rare and debilitating illnesses.
The Company holds an exclusive licence to sell Lojuxta (lomitapide) for adults, across the EU and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia, which impairs the body's ability to remove LDL cholesterol ("bad" cholesterol) from the blood. This typically results in extremely high blood LDL cholesterol levels leading to aggressive and premature narrowing and blocking of arterial blood vessels. If left untreated, heart attack or sudden death may occur in childhood or early adulthood.
Amryt's lead drug candidate, AP101 (Episalvan), is a potential treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment. It is currently in Phase 3 clinical trials.
Amryt's earlier stage product AP102 is focused on developing novel, next generation somatostatin analogue ("SSA") peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing's disease.
Anagenesis is a preclinical‐stage stem cell-based company focused on developing novel treatments for genetic and age-related muscle degenerative diseases with unmet medical needs.
A wide spectrum of diseases in which specific tissues are lost or damaged remain incurable. This reflects a lack of drugs to promote regeneration or of transplantable cells to replace those that are missing. One example of this urgent unmet need are the human conditions that lead to degeneration of skeletal muscle, ranging from muscular dystrophies and neuromuscular disease to muscle-wasting caused by disuse. However, to date, it has not been possible to generate muscle cells in sufficient quantity for high-throughput drug screening, or sufficient purity for cell-based therapy.
Patented new technologies licensed-in by Anagenesis have changed all this. Using stem cells as a renewable source, Anagenesis scientists first generated the natural embryonic precursors of skeletal muscle then devised protocols for turning the precursors into contractile muscle fibers in the culture dish. The resulting muscle cells are purer and more abundant than any before and successfully colonize damaged muscle when transplanted in vivo. Moreover, when stem cells from mice with muscle disorders are used, the resulting muscle fibers show characteristic disease-related defects in culture. The time is therefore ripe for drug screening to enhance muscle regeneration and/or correct disease phenotypes, and for a reasoned approach to therapeutic muscle reconstruction.
Anagenesis has exclusive rights to two key patents from the French national biomedical research agency INSERM. Two main activities will generate revenues: a) Cell therapy for genetic muscle disorders b) Cell-based screening of small molecules
Anagenesis already secured its first private funding from the AFM (French muscular dystrophy association) to develop applications in the skeletal muscle therapeutic area. http://anagenesis-biotech.com/
Anima Biotech, Inc.
Anima Biotech is advancing Translation Control Therapeutics, the first and only platform for the discovery of small molecule drugs that specifically control mRNA translation as a new strategy against hard and undruggable targets in many diseases.
Anima’s proprietary technology enables visualization and monitoring of target protein translation via pulses of light emitted by ribosomes. The fully automated high-throughput screening system discovers small molecules that modulate the light, as they decrease or increase the target protein’s production. The platform integrates proprietary technologies in biology, bioinformatics, image analysis, big data analysis and artificial intelligence algorithms in a cloud computing software architecture.
Anima is developing an internal pipeline across multiple therapeutic areas with high unmet need and hard targets. Current programs are in Fibrosis (inhibiting the synthesis of Collagen type I), Viral infections (Respiratory Syncytial Virus – interfering with viral protein synthesis), Oncology (C-Myc translation inhibitors) and Huntington's disease (monitoring mutant Huntingtin translation pausing).
Anima’s Translation Control Therapeutics platform is strategically designed for partnering with Pharma. The power of Anima’s approach was solidified with a $1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets. Anima’s technology has been further validated by 5 granted patents, 14 peer reviewed publications and 17 scientific collaborations.
Anocca is a Swedish privately funded biotech company developing technologies, diagnostics and therapeutic strategies for individualized management of oncological, autoimmune and inflammatory conditions through harnessing adaptive immunity.
At the core of Anocca is a proprietary immunotechnology platform that enables immunotherapeutic target discovery, validation and product development in a clinical setting where individualized patient assessment and tailored solutions are the focus. This technological platform is integrated with high-performance manufacturing strategies within state of the art GMP facilities that have been approved by the Swedish Medical Products Agency.
Athira Pharma is a drug development company striving to improve human health by advancing new therapies for neurodegenerative diseases like Alzheimer’s and Parkinson’s. Our innovative approach is focused on turning brain degeneration into regeneration, achieved by re-establishing lost connections and restoring lost function.
ATRIVA aims to develop new antiviral therapies against different respiratory viral infections. Founded in 2015, ATRIVA attracted seasoned experts in virology and drug development to form a unique venture targeting the fast and successful validation of a novel approach to fight infectious diseases Inhibitors of certain cellular signaling pathways, the so called “MEK-Inhibitors”, have shown a superior antiviral activity by blocking viral replication. This creates an unprecedented potential for truly efficacious and safe therapeutics against numerous viral infections.
ATRIVA closed a seed financing of € 3 Mn in late 2016. The proceeds of this allows the company to reach clinical development with its lead project ATR-002 for influenza in high-risk patients. We invite you to explore our approach and pipeline presented on this website and encourage you to contact us directly.
Bone Therapeutics is a leading cell therapy company addressing high unmet medical needs in the field of orthopaedics and bone diseases.
Bone Therapeutics has a broad, diversified portfolio of bone cell therapy solutions and viscosupplement in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.
Our technology is based on a unique, proprietary approach to bone regeneration which turns undifferentiated stem cells into “osteoblastic”, or bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.
Our primary clinical focus is ALLOB ® , an allogeneic “off-the-shelf” cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. In addition, Bone Therapeutics is also developing an enhanced viscosupplement, JTA-004, for the treatment of knee osteoarthritis.
Bone Therapeutics is also conducting preclinical research on next generation products such as combined cell-matrix products for large bone defects and maxillofacial applications.
Bone Therapeutics’ cell therapy products are manufactured to the highest GMP standards and are protected by a rich Intellectual Property estate covering nine patent families.
Cantargia is a Swedish biotechnology company that specialises in the development of pharmaceuticals for various types of cancer diseases and autoimmune/inflammatory diseases. Our development programme includes the product candidate CAN04, which is currently in phase IIa clinical studies, as well as our discovery project CANxx. The company is listed on OMX Stockholm’s Main List (Small Cap).
Cantargia AB was formed in 2009-2010 with the aim of refining a discovery by Professor Thoas Fioretos and Doctor Marcus Järås of Lund University. Their research showed that leukaemia stem cells express a protein on their surface – IL1RAP – that is not expressed to as great a degree on normal stem cells. Further research by Cantargia showed that this protein is also expressed in solid tumours present in many other types of cancer.
Cyxone AB is a clinical biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders.
Cyxone’s technologies have the potential to address an unmet need to develop new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company’s development portfolio comprises Rabeximod in a clinical phase II program for RA and T20K that soon will enter clinical phase I for MS.
What drives us is the realization that there is still a lot to be won in the treatment of cancer. Not only in terms of survival, but also in the quality of life of people living with cancer. DCprime aims to make a meaningful contribution to the field of immuno-oncology, by bringing highly relevant and safe cancer vaccines to market. This requires a deeper understanding of underlying disease mechanisms, including interaction between tumour and immune system, in which we continue to invest. We anticipate that disruptive new cancer treatments will be the result of collaborative efforts, so we strive to work together with relevant academic groups, hospitals and other companies to help shape a new era in cancer immunotherapeutics.
Dyadic International, Inc. is a global biotechnology company based in Jupiter, Florida with a foreign subsidiary, Dyadic Nederland, BV, which maintains a small satellite office in Wageningen, the Netherlands. Over the past two decades, the Company has developed a method for producing commercial quantities of enzymes and other proteins required for the production of industrial enzymes and has successfully licensed this technology to third parties such as Abengoa Bioenergy, BASF, Codexis and others. This technology is based on the Myceliophthora thermophila fungus, which the Company named C1. The C1 technology is a robust and versatile fungal expression system for gene discovery, development, expression and production of enzymes and other proteins.
EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company based in Shanghai with a proprietary, unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) that generates bispecific molecules with antibody-like properties. With this innovative platform, EpimAb is creating a potentially game-changing pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients.
Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.
Gain Therapeutics is funded by private Swiss investors and the TiVenture fund and will be based in Lugano (Switzerland), with a branch operating in Barcelona. The team of researchers working in the Minoryx lab at the Barcelona Science Park has been absorbed by the new spin-off, under the scientific management of Dr Xavier Barril, ICREA researcher and co-founder of Minoryx Therapeutics, who originated the technology.
Genclis commercializes pre-clinical and cellular models in allergy and autoimmunity to evaluate novel therapeutic, probiotic and nutritional solutions.
Genclis assists commercial partners in:
Evaluating intrinsic allergenicity of pharmaceutical, food and cosmetic ingredients;
Etablishing industrial procedures to control or suppress ingredient’s allergenicity;
Genclis engages in exclusive industrial partnerships for co-development of Transcription Infidelity Assisted Sequential Immunization programs for infectious and immune diseases. Genclis manufactures and commercializes cutting edge reagents for diagnostic and preclinical use.
GeNeuro is a clinical stage pharmaceutical company developing a new approach to the treatment of autoimmune diseases, including multiple sclerosis (MS) and Type 1 Diabetes (T1D) associated with pathogenic proteins expressed by human endogenous retroviruses (HERV), viral genes that account for 8% of human DNA.
This novel approach is the result of 25 years of research on endogenous retroviruses, including 15 within Institut Mérieux and INSERM, before the creation of GeNeuro in 2006. This research has allowed us to uncover and understand the action of a factor potentially causative of multiple sclerosis, the envelope protein (Env), which is produced by a pathogenic member of the human endogenous retrovirus-W family (pHERV-W). The presence of pHERV-W Env in brains of MS patients may be an important driver of the neurodegenerative phenomena characterizing this disease.
GlyCardial Diagnostics is a spin-off company of the IR-Hospital de la Santa Creu i Sant Pau and the Spanish National Research Council (CSIC) focused on the development of a novel in vitro diagnostic device for myocardial ischemia. The technology is based on the detection of Apo J-Glyc in blood as a biomarker for the early diagnosis of cardiac ischemia and the prediction of patient’s evolution after an ischemic event. The novelty and the potential impact of the Apo J-Glyc project has been recognized by several entities at a national and international level.
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on a proprietary arenavirus platform that is designed to reprogram the body’s immune system.
We are using our ‘‘off-the-shelf’’ technologies, VaxWave®* and TheraT®*, to elicit directly within patients a powerful and durable response of antigen-specific killer T cells and antibodies, thereby activating essential immune defences against infectious diseases and cancers. We believe that our technologies can meaningfully leverage the human immune system for prophylactic and therapeutic purposes by eliciting killer T cell response levels not achieved by other published immunotherapy approaches.
Our platform technology is based on engineering arenaviruses to carry and deliver virus-specific or tumor-specific genes to dendritic cells, which are natural activators of killer T cells, also known as cytotoxic T cells, or CD8+ T cells. We believe we are the first to reengineer arenaviruses for therapeutic purposes. Read more
Our lead infectious disease product candidate, HB-101, is currently in a Phase 2 randomized, double-blinded clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
Our lead oncology product candidates, HB-201 and HB-202, are in development for the treatment of human papillomavirus-positive cancers. We plan to file an investigational new drug application, or IND, with the U.S. Food and Drug Administration for HB-201 and HB-202 in the first half and second half of 2019, respectively. Read more
We have entered into a strategic partnership with Gilead Sciences, Inc., to accelerate building a pipeline of additional infectious disease product candidates in a cost efficient manner.
IGEM Therapeutics is a UK Immuno-Oncology company developing novel IgE antibodies to treat cancer. IgE has evolved to kill tissue-dwelling multicellular parasites endowing it with several key features that make it ideal for the treatment of solid tumours which also mostly reside in tissue. The epsilon constant region of IgE binds very tightly to its cognate receptor (FcεRI) on the surface of immune effector cells including macrophages, monocytes, basophils and eosinophils. This interaction is up to 10,000 fold greater than the gamma chain of IgG has for its equivalent receptor and this results in the majority of IgE molecules being permanently attached to the surface of immune effector cells. The latter are therefore primed and ready to destroy cells expressing the antigen recognised by the IgE. As a result, IgE is able to permeate tissues more effectively than IgG and stimulate significantly greater levels of both ADCP (antibody-dependent cell-mediated phagocytosis) and ADCC (antibody-dependent cell-mediated cytotoxicity), the two main mechanisms by which immune effector cells can kill tumour cells. IgE also has a significantly longer tissue half life than IgG (2 weeks versus 2 – 3 days) which also suits it for a role in the destruction of solid tumours.
The company’s lead programme targets the folate receptor alpha (FR alpha) and an anti-FR alpha IgE antibody is currently in a phase 1/2a trial to treat ovarian cancer. This is the world’s first IgE therapeutic to enter the clinic.
IGEM is also developing a novel antibody platform technology based on protein and glyco-engineering of the epsilon constant region.
IKU is a decentralized research organization (DRO) for staking and monetizing open science. The IKU platform allows you to create, license, and trade fundable bio r&d datasets as alternative liquidity methods for bio r&d. The mission is to break down walled gardens and accelerate bio-innovation by offering a patent work-around with a blockchain-based licensing mechanism accessible by anyone.
Our first project, the NeuroDRO, is the first decentralized offering to distribute the cost, risk, and ownership of a scientific breakthrough addressing neurodegeneration, uncovered by emerging technology: non-targeted metabolomics using ultra-high-resolution mass spectrometry, capable of generating 100x more data points than traditional systems.
The purpose of the NeuroDRO is to ultimately prevent neurodegeneration and create a research library of over 10,000,000 data points for aging and neurodegenerative disorders. IKU will analyze comprehensive clinical and biochemical data relevant to and useful for the treatment of neurodegenerative disorders. Initial data generation will be executed via the PH III Plasmalogen NeuroTrial. NeuroDRO research on the plasmalogen hypothesis is supported by the University of Pennsylvania, Alzheimer’s Association, Duke University, and the NIH.
We propose a digital DRO infrastructure for funding, owning, and developing high demand, 100x key value experiments to exponentially speed up the cycle in which actionable bio-information emerges for investors, scientists, and most importantly human longevity.
Imcyse is pioneering the development of a new class of active, specific immunotherapeutics: ImotopesTM. Imcyse’s new technology platform is based on the discovery of modified synthetic peptides to block the immune processes causing immune-mediated diseases. Imcyse’s ImotopesTM offer the possibility to cure severe chronic diseases for which there is no satisfactory therapeutic alternative. The technology can also prevent the immunogenic responses that weaken the efficiency of chronic therapies.
Our vision is to become a major player in active specific immunotherapy for the curative treatment of autoimmune and allergic diseases.
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The company’s lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm.
Innovate is a publicly traded (Nasdaq: INNT) clinical stage biotechnology company focused on developing novel medicines for autoimmune and inflammatory diseases with unmet needs. Our pipeline includes drug candidates for celiac disease, NASH, Crohn's, and ulcerative colitis. Innovate is led by a strong management team with extensive drug development experience and a history of bringing novel therapeutics to market. All global rights to the products, which are backed by more than 150 patents worldwide, are owned by the company.
Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer.
Our company was founded in 2008 with a vision of pioneering a potentially new approach to treating patients with cancer and other serious diseases.
Our novel approach to cancer treatment involves targeting the export of specific proteins in a cancer cell’s nucleus with SINE technology (Selective Inhibition of Nuclear Export).
Our primary focus is on developing novel drugs which we hope will help treat patients with certain blood cancers or solid tumor malignancies.
Kuros has spent more than a decade refining technologies that instruct the body to form bone using targeted and controlled mechanisms of action.
The past twenty years have seen a number of advancements in bone repair, from the increasing use of bioactive scaffolds to the introduction of growth factors and cell-based allografts. Current bone graft selection includes autograft, allograft, demineralized bone matrix, ceramics, mesenchymal stem cells, and recombinant human bone morphogenetic protein. Each pose their respective advantages and disadvantages and are the focus of ongoing research investigating the safety and efficacy of their use.
The scientific leaders at Kuros have spent more than a decade advancing the science of orthobiologics by refining technologies that instruct the body to form bone in a targeted and controlled fashion.
Kuros Biosciences, a spin-off of the Eidgenössische Technische Hochschule Zürich (ETHZ), together with the University of Zürich and at the California Institute of Technology (CalTech) developed the proprietary 'TG Hook technology' which led to our biologics program. In early 2017 Kuros acquired Xpand Biotechnology, adding substantial expertise in the surface science of orthobiologics & delivering the next generation MagnetOs family of bone grafts to our portfolio.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of metastatic solid tumors, including the Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and the HER2/neu program (TPIV100/110) for breast cancer, currently in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ that can enhance the ability of the immune system to recognize and destroy diseased cells.
Since our creation, the know-how and strong involvement of our people have been essential elements in our development. Our 130 employees, representing more than 20 nationalities, have major holdings in our company’s stock and share a common ambition: to have a real and positive impact on global health.
All of our people are able to become shareholders soon after they start working at MedinCell. In this way, they become real partners, they are strongly involved, and their interests are clearly aligned with those of the Company.
It also helps to guarantee that our people benefit directly from the Company’s success. Moreover, because our people are our main shareholders, we remain independent and stay focused on our mission of Better Medicine For All.
The desire to involve our people in the Company’s success has led to the development of a dynamic entrepreneurial culture at all levels of the business in the service of operational effectiveness.
Metys Pharmaceuticals is developing MP-101 to prevent and treat chemotherapy-induced peripheral neuropathy, an uncomfortable and troubling side effect of several important cancer treatments.
MP-101 is an orally-active modulator of glutamate signalling in spine and brain. Glutamate signalling has long been a sought-after target for the development of new central nervous system drug candidates. MP-101 is a particularly well-suited candidate, with outstanding pharmaceutic properties; it is a small molecule, obtained by a straight-forward chemical manufacturing process. It is also orally active in a wide range of rodent models of central nervous system disorders, such as depression, cognition, or neuropathic pain.
MP-101 is a patent-pending non-racemic mixture of the left-handed and right-handed versions (the "enantiomers") of dimiracetam. It is not a one-to-one mixture (a "racemate"), but a ratio that has been chosen because it is - unexpectedly - considerably more potent pharmacologically than the racemate. While the one-to-one mixture has long been known to be superior to either of the two single-handed enantiomers alone, Metys Pharmaceuticals has discovered that certain mixtures of dimiracetam enantiomers are far more potent still.
Metys Pharmaceuticals has licensed the world-wide exclusive rights to racemic dimiracetam from Neurotune AG, including the entire dossier of regulatory studies supporting clinical trials of racemic dimiracetam. Metys Pharmaceuticals now aims to use these pharmacological, toxicological and clinical data obtained with racemic dimiracetam to support the future clinical trials of MP-101.
Modern medicine relies on antibiotics and It is difficult to envisage a world without antibiotic-drugs, yet, antibiotic-resistance is rapidly spreading around the globe. Omnix Medical, founded in 2015, is a pre-clinical company developing an arsenal of novel antibiotic-agents that target Multi-Drug-Resistant bacteria.
Omnix’s agents are based on antimicrobial peptides, biochemically engineered to be compatible for therapeutic use, they are stable and employ a unique MOA that eliminates bacteria upon contact with no toxic effects. Omnix is focused on the Multi-Drug-Resistant Gram(-) ESKAPE pathogens: K. pneumonia spp, A. baumannii, P. aeruginosa and Enterobacter spp. These bacteria are the most urgent threats to public health, according to the WHO and CDC, while the drugs intended to fight them become ineffective due to antibiotic-resistance.
Omnix proprietary technology is patent-protected and allows for the design and synthesis of an arsenal of novel and efficient antimicrobial peptides. Omnix Medical’s lead peptide, OMN6, has already demonstrated its safety and efficacy in animal-models and has been granted QIDP designation by the FDA.
Omnix Medical has raised funds from both government and private sectors and is addressing an enormous and rapidly growing market opportunity. Omnix is dedicated to providing a safer, more efficient alternative to currently available antibacterial therapies.
Oryzon is a public clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics.
From its founding in 2000 through 2008, the company focused its efforts in growing a genomics diagnostics business model, providing genomics services to the pharmaceutical industry in Europe. In 2008, with the acquisition of Crystax Pharmaceuticals, we started our drug discovery programs in oncology and neurodegenerative diseases. Our business model is to develop our proprietary drug candidates through clinical phase II, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization.
Oryzon is listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). In the period 2015-2016, the company raised €32M, with additional Pipes in 2017 (€18.2M) and 2018 (€13M) where the company incorporated specialized investors from US and Europe.
The company has a broad and growing portfolio, with two compounds in clinical trials, iadademstat (ORY-1001), a highly potent and selective LSD1 inhibitor that has been granted orphan-drug status by EMA, in Phase IIa in oncology, and vafidemstat (ORY-2001), a dual LSD1/MAO-B inhibitor for the treatment of multiple sclerosis, Alzheimer’s disease and other neurodegenerative diseases, in Phase IIa, as well as another compound in preclinical development, ORY-3001, a selective LSD1 inhibitor for the treatment of non-oncological diseases, and additional programs in other cancer indications.
From 2014 to 2017 the company had a collaboration with Roche relating to our lead oncology program, iadademstat, and received +$23M. This asset is now being developed by Oryzon. The company has also obtained competitive US and European grants in the amount of €8M to support the development of vafidemstat since the start of our CNS research.
The company has a seasoned executive management with vast experience in the industry.
Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a French-Belgian biotech company that develops an innovative class of active immunotherapies to treat cancers. This cancer vaccine contains proprietary, potent, and scalable plasmacytoid dendritic cell line (PDC*line), whose remarkable characteristics make them excellently suited for immunotherapy. PDC*line is much more potent to prime and boost antitumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors.
Perseo pharma takes its name from Perseus, the hero of Greek mythology who, by wearing the Cap of Invisibility, was able to slay the Gorgon Medusa whose gaze was turning onlookers into stone. Perseo pharma’s therapeutic enzymes, with their stealth coating, are able to invisibly reach their targets so as to slay the disease. Over the past 30 years and the first development of biologics, 30 therapeutic enzymes have been approved by EMA and FDA (1/4 of all approved biologics). Therapeutic enzymes address a wide variety of indications, ranging from rare genetic diseases (enzyme replacement therapies) to oncology (key tumor-element depletion therapies). However, existing therapeutic enzymes exhibit both efficacy issues (lack of systemic stability, low residence time) and toxicity issues (up to 80% anti-drug reactions, immunogenicity).
Primex Pharmaceuticals is a leading global innovative anaesthesia company, expanding in paediatric pharmaceuticals.
Primex brings a broad portfolio of anaesthesia products helping patients undergo a wide range of medical procedures, including a novel, oral solution for paediatric sedation now approved in several markets in the European Union.
Primex Pharmaceuticals will continue to identify and bring to the market new medications that complete the Triad of Anaesthesia. In addition, the Group includes a complimentary range of local anaesthetics and dental products under the OGNA® brand.
Primex Pharmaceuticals’ global partner network operates in over 40 countries. The company is headquartered in Switzerland; all Primex products are manufactured in Europe. Primex Pharmaceuticals has proven underlying business operations and historical strong revenue growth.
RhoVac is a biotech company with an asset, RV001, in clinical phase 2b. RV001 is an antigen mediated immuno-therapy that triggers the immune system to target and destroy metastatic cells, and metastatic cells only, on the basis of their unique over-expression of the protein RhoC, a protein that lends to metastatic cells their lethal ability to migrate and infiltrate other tissues. In its phase 2b (ca. 175 patients) trial, RV001 is being studied for its ability to prevent cancer recurrence (measured as PSA rise) after radical prostatectomy in prostate cancer. But the RhoC targeting principle is probably generally applicable to other metastatic cancers too. As such, RhoVac is looking for a licensee or an acquirer among large oncology focused pharmas after the phase 2b study. Phase 2b results will be at hand mid 2021.
STALICLA is a mission-driven biotech, with a unique patient centric vision, that is poised to become a disruptive industry challenger and future global leader in personalized treatment options for patients with Autism Spectrum Disorder (ASD). At STALICLA, we have developed an innovative algorithm platform that uses robust sets of clinical signs and symptoms with big data analytics to identify subgroups of ASD patients. By identifying these subgroups, we aim to offer repurposed drugs that provide more effective, personalized treatment options.
The company was founded in Geneva, Switzerland in May 2017 by today’s CEO Lynn Durham, a biotech entrepreneur with a lifelong involvement with the autism community. STALICLA has established a research partnership with the Greenwood Genetic Center, South Carolina, USA, a leading translational research center in genetics and neurodevelopmental disorders, including ASD.
Themis Bioscience is an international biotech company that successfully develops vaccines against emerging and specialist indications. Exploiting the full potential of our proprietary Themaxyn® platform we are able to identify and rapidly advance vaccine candidates at various stages of development. Based on a well-proven base technology, the Themaxyn® platform offers both, an excellent safety profile and a validated manufacturing process. Themis Bioscience was founded in 2009 by a group of internationally renowned vaccine and biotech executives in Vienna, Austria. In 2014 Themis successfully completed a phase I clinical trial with our Chikungunya vaccine in Austria. Themis continues to head the race for preventing emerging infectious diseases and started a phase II clinical trial with our Chikungunya vaccine in 2016 and a phase I clinical trial with our Zika vaccine in 2017.
TOLREMO therapeutics AG (“TOLREMO”) is a Swiss biotechnology company that was spun out of ETH Zurich in 2017. Based on cutting-edge science and guided by pioneering real-world medicine, TOLREMO created a broad cancer drug resistance platform that provides a unique entry point into a major clinical problem. In two parallel R&D programs the company develops resistance-breaking add-on therapies that extend the therapeutic benefit of oncogene-targeting cancer drugs (Adaptive Drug Resistance Program) and anti-angiogenic cancer drugs (Hypoxia-Driven Drug Resistance Program). TOLREMO’s unique drug resistance platform has the potential to catalyze a new wave of potent resistance-breaking molecules that will meaningfully extend the lives of patients suffering from cancer.
TOLREMO is headquartered on the ETH Hönggerberg campus in Zurich, Switzerland, where the company is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and cutting-edge technology platforms. TOLREMO enjoys broad access to state-of-the art ETH infrastructure including laboratory space and an industry standard robotic screening facility.
With innovation, creativity and the latest technology, CEO Reto Naef and his team of experts at TOPADUR PHARMA AG ("TOPADUR") won not only the Swiss Technology Award in 2016 but also the prestigious "Swiss Innovative Challenge" in November 2017. The very promissing young and dynamic biotech start-up from Schlieren ZH is able now to move into global markets and continually create new jobs. TOPADUR develops two promising drugs in the area of wound healing for the treatment of non-healing wounds and to avoid excessive scar formation in burn wounds. The active substance and medical compound "TOP-N53" could offer all diabetics with chronic foot wounds essential support in avoiding amputations and extend their lives. The drugs produced by TOPADUR cover major medical requirements that burden the global healthcare budget to the tune of more than USD 24 billion every year.
UGA Biopharma’s core area of business is the contract development of biologics and biosimilars. This involves all the necessary steps from cell line development and bioprocess development to the development of purification and analysis processes. UGA Biopharma’s unique selling feature is also that it offers its customers what are known as ready-to-use biosimilar cell lines.
The company supplies its customers in Germany and abroad from its headquarters in Hennigsdorf and already has several users with UGA products in clinical trials or who have already received market approval.
Versameb AG is a regenerative medicine research and development company. Regenerative medicine is one of the largest health challenges and unmet medical needs affecting a majority of the world‘s aging population. Our mission is to design novel technologies for local growth factor delivery with a dramatically prolonged biological activity. We are aiming to provide definitive, simple and highly valuable solutions for restoring tissue functions, notably joint, bone, muscle and wound healing, all significant unmet medical needs. Our expertise, knowledge and intellectual property will allow us to deliver game-changing solutions in this field.